

# Voting Questions for the Committee

---

1. Does the committee recommend a trivalent 2024-2025 formulation for egg-based influenza virus vaccines in the U.S. that contains the following virus strains:
  - An A/Victoria/4897/2022 (H1N1)pdm09-like virus;
  - An A/Thailand/8/2022 (H3N2)-like virus; and
  - A B/Austria/1359417/2021 (B/Victoria lineage)-like virus
2. Does the committee recommend a trivalent 2024-2025 formulation for cell- and recombinant-based influenza vaccines in the U.S. that contains the following virus strains:
  - An A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
  - An A/Massachusetts/18/2022 (H3N2)-like virus; and
  - A B/Austria/1359417/2021 (B/Victoria lineage)-like virus
3. For U.S.-licensed quadrivalent influenza vaccines intended for ex-U.S. distribution, does the committee recommend inclusion of a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus as the 2<sup>nd</sup> influenza B strain in the vaccine